← Back to Search

Osteoporosis Agent

Group 1- Treatment for Osteoarthritis

Phase 2
Waitlist Available
Led By Christopher Ritchlin, MD
Research Sponsored by Michael Zuscik
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year.
Awards & highlights

Study Summary

This trial is testing if teriparatide can help improve knee osteoarthritis by looking at changes in biomarkers, function, and patient reports.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Knee MRI
Secondary outcome measures
Flexed Knee Radiograph
GAITRite
PROMIS Depression
+6 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Group 1- TreatmentActive Control1 Intervention
20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
Group II: Group 2- PlaceboPlacebo Group1 Intervention
Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.

Find a Location

Who is running the clinical trial?

Michael ZuscikLead Sponsor
Duke UniversityOTHER
2,358 Previous Clinical Trials
3,419,994 Total Patients Enrolled
29 Trials studying Osteoarthritis
4,185 Patients Enrolled for Osteoarthritis
Milton S. Hershey Medical CenterOTHER
492 Previous Clinical Trials
2,798,746 Total Patients Enrolled
7 Trials studying Osteoarthritis
293 Patients Enrolled for Osteoarthritis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Teriparatide as a Chondroregenerative Therapy in OA
Christopher Ritchlin 2017. "Teriparatide as a Chondroregenerative Therapy in OA". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03072147.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top